Publications by authors named "A H Honkoop"
Article Synopsis
- CDK4/6 inhibitors combined with endocrine therapy improve outcomes for patients with hormone-receptor positive, HER2-negative advanced breast cancer, but evidence comparing first-line and second-line use is limited.
- The phase 3 SONIA trial involved 1,050 patients and showed no significant overall benefit for using CDK4/6 inhibitors first-line compared to second-line (31.0 vs. 26.8 months median progression-free survival).
- Although first-line treatment led to longer duration of CDK4/6 therapy and more severe side effects, the quality of life was similar for both treatment timing, questioning the necessity for first-line CDK4/6 inhibitor usage in all cases.
Purpose: Patients with chemotherapy-induced ovarian function failure (CIOFF) may experience ovarian function recovery (OFR). Earlier, we showed that OFR during treatment with anastrozole impacted the prognosis of hormone receptor-positive (HR+) breast cancer (BC) patients with CIOFF. Here, we present the long-term follow-up results.
View Article and Find Full Text PDFBackground: Obesity has been associated with an adverse prognosis and reduced efficacy of endocrine therapy in patients with hormone receptor-positive (HR+) breast cancer (BC). This study determines the prognostic and predictive effect of body mass index (BMI) on the disease-free survival (DFS) of postmenopausal HR+ BC patients.
Methods: Patients were identified from the DATA study (NCT00301457), a randomized controlled trial evaluating the efficacy of 6 vs 3 years of anastrozole after 2 to 3 years of adjuvant tamoxifen in postmenopausal women with HR+ BC.
Exploratory analyses of high-dose alkylating chemotherapy trials have suggested that BRCA1 or BRCA2-pathway altered (BRCA-altered) breast cancer might be particularly sensitive to this type of treatment. In this study, patients with BRCA-altered tumors who had received three initial courses of dose-dense doxorubicin and cyclophosphamide (ddAC), were randomized between a fourth ddAC course followed by high-dose carboplatin-thiotepa-cyclophosphamide or conventional chemotherapy (initially ddAC only or ddAC-capecitabine/decetaxel [CD] depending on MRI response, after amendment ddAC-carboplatin/paclitaxel [CP] for everyone). The primary endpoint was the neoadjuvant response index (NRI).
View Article and Find Full Text PDFArticle Synopsis
- * 363 out of 422 men participated in the study, revealing that men had a higher average global health status score compared to women with BC, but also reported common symptoms like fatigue and pain.
- * Overall, men with BC reported similar or better QoL than women, suggesting a need for future research on how treatment affects their symptoms and wellbeing over time.